IlluminaXSWX:ILMN -0.79%76 Buyback Yield % is 2.76 as of Jun. 27, 2026, which is 500% above its 10-year median of 0.46. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Illumina ranks better than 82.76% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Illumina's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Illumina's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Illumina's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a Buyback Yield % of 2.76 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Illumina and its competitors. This is 500% above median its historical median of 0.46. According to the industry distribution chart, Illumina ranks #15 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 17.2%.
Is Illumina's Buyback Yield % too high?
Illumina's current Buyback Yield % of 2.76 is 500% above median its 10-year median of 0.46. Based on the distribution chart, Illumina ranks #15 out of 87 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Buyback Yield % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #15 out of 87 companies for Buyback Yield %. This places Illumina in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Illumina and its competitors. Illumina's current Buyback Yield % is 2.76, which is 500% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Buyback Yield % of 2.76. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Buyback Yield % is 2.76, which is 500% above median its 10-year median of 0.46. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Buyback Yield % is 2.76 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.
Key valuation signals for XSWX:ILMN:
Buyback Yield %: 2.76 (500% above median its 10-year median of 0.46)
GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
